A proposed medication score for long-term trials of treatment of canine atopic dermatitis sensu lato.
atopic
canine
dog
medication
score
treatment
trial
Journal
The Veterinary record
ISSN: 2042-7670
Titre abrégé: Vet Rec
Pays: England
ID NLM: 0031164
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
20
07
2020
revised:
08
09
2020
accepted:
06
11
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
16
6
2021
Statut:
ppublish
Résumé
The use of concurrent medications is necessary in trials of treatment of canine atopic dermatitis. Our aim was to use the best available evidence to construct and then to validate a medication score (MS) formula that will estimate the impact of concurrent medications on trial outcomes. Trials of 15 interventions were scrutinized to find those that were consistent in terms of specific medication, administration route and dosage regimen. A MS was constructed in five steps, starting from assigning a score of 1 for each day on oral prednisone, prednisolone or methylprednisolone at 0.5-1.0 mg/kg. The MS score was validated using the clinical records of 35 dogs with atopic dermatitis that had been treated for a period of 12 ± 2 weeks with six of these medications and compared with a previously published non-validated MS. A MS could be assigned to eight treatments, six of which had been administered to the 35 dogs. A positive correlation was seen with the previously published MS and a negative correlation with changes in lesional and pruritus scores. This MS may be a useful tool in new studies evaluating the efficacy of treatments in canine atopic dermatitis.
Sections du résumé
BACKGROUND
The use of concurrent medications is necessary in trials of treatment of canine atopic dermatitis. Our aim was to use the best available evidence to construct and then to validate a medication score (MS) formula that will estimate the impact of concurrent medications on trial outcomes.
METHODS
Trials of 15 interventions were scrutinized to find those that were consistent in terms of specific medication, administration route and dosage regimen. A MS was constructed in five steps, starting from assigning a score of 1 for each day on oral prednisone, prednisolone or methylprednisolone at 0.5-1.0 mg/kg. The MS score was validated using the clinical records of 35 dogs with atopic dermatitis that had been treated for a period of 12 ± 2 weeks with six of these medications and compared with a previously published non-validated MS.
RESULTS
A MS could be assigned to eight treatments, six of which had been administered to the 35 dogs. A positive correlation was seen with the previously published MS and a negative correlation with changes in lesional and pruritus scores.
CONCLUSION
This MS may be a useful tool in new studies evaluating the efficacy of treatments in canine atopic dermatitis.
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19Informations de copyright
© 2021 British Veterinary Association.
Références
Saridomichelakis MN, Olivry T. An update on the treatment of canine atopic dermatitis. Vet J. 2016;207:29-37.
Olivry T, Foster AP, Mueller RS, Mcewan NA, Chesney C, Williams HC. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol. 2010;21:4-22.
Olivry T, Bizikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update. Vet Dermatol. 2013;24:97-e26.
Olivry T, Deboer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol. 2010;21:233-48.
Olivry T, DeBoer DJ, Favrot C, Jackson HA, Mueller RS, Nuttall T, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210.
Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol. 2010;21:456-62.
Mueller RS, Fieseler KV, Fettman MJ, Zabel S, Rosychuk RAW, Ogilvie GK, et al. Effect of omega-3 fatty acids on canine atopic dermatitis. J Small Anim Pract. 2004;45:293-7.
Mueller RS, Veir J, Fieseler KV, Dow SW. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study. Vet Dermatol. 2005;16:61-8.
Litzlbauer P, Weber K, Mueller RS. Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega. Cytokine. 2014;66:54-9.
Ohshima-Terada Y, Higuchi Y, Kumagai T, Hagihara A, Nagata M. Complementary effect of oral administration of Lactobacillus paracasei K71 on canine atopic dermatitis. Vet Dermatol. 2015;26:350-e75.
Hobi S, Klinger C, Classen J, Mueller RS. The effects of a topical lipid complex therapy on dogs with atopic dermatitis: a double blind, randomized, placebo-controlled study. Vet Dermatol. 2017;28:369-e84.
Fischer N, Tarpataki N, Leidi F, Rostaher A, Favrot C. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol. 2018;29:337-e118.
González J-L, Zalve V, Fernández-Caldas E, Cases B, Subiza J-L, Casanovas M. A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan-Dermatophagoides farinae allergoid targeting dendritic cells. Vet Dermatol. 2018;29:449-e152.
Osumi T, Shimada T, Sakaguchi M, Tsujimoto H. A double-blind, placebo-controlled evaluation of orally administered heat-killed Enterococcus faecalis FK-23 preparation in atopic dogs. Vet Dermatol. 2019;30:127-e36.
Michels GM, Ramsey DS, Walsh KF, Martinon OM, Mahabir SP, Hoevers JD, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol. 2016;27:478-e129.
Moyaert H, Van Brussel L, Borowski S, Escalada M, Mahabir SP, Walters RR, et al. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet Dermatol. 2017;28:593-e145.
Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;114:207-8.
Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol. 2001;81:255-69.
DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. Vet Immunol Immunopathol. 2001;81:271-6.
Willemse T. Atopic skin disease-a review and a reconsideration of diagnostic criteria. J Small Anim Pract. 1986;27:771-8.
Prelaud P, Guaguere E, Alhaidari Z, Faivre N, Héripret D, Gayerie A. Reevaluation of diagnostic criteria of atopic dermatitis. Rev Med Vet. 1998;149:1057-64.
Favrot C, Steffan J, Seewald W, Picco F. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol. 2010;21:23-31.
Olivry T, Saridomichelakis M, Nuttall T, Bensignor E, Griffin CE, Hill PB. Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Vet Dermatol. 2014;25:77-e25.
Hill PB, Lau P, Rybnicek J. Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol. 2007;18:301-8.
Rybníček J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol. 2009;20:115-22.
Petrie A, Watson P. Statistics for veterinary and animal science, 2nd ed. Oxford, UK: Blackwell Publishing; 2006.
Dip R, Carmichael J, Letellier I, Strehlau G, Roberts E, Bensignor E, et al. Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis. BMC Vet Res. 2013;9:173.
Feld D, Marsella R, Ahrens K. A prospective, double-blinded, controlled pilot study to evaluate the effects of cyclosporine (Atopica) on skin barrier function in canine atopic dermatitis by measurement of trans-epidermal water loss. Int J Appl Res Vet Med. 2014;12:18-23.
Ferrer L, Alberola J, Queralt M, Brazis P, Rabanal R, Llenas J, et al. Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis. Vet Rec. 1999;145:191-4.
Kovalik M, Taszkun I, Pomorski Z, Kozak M, Pomorska D, Szczepanik M, et al. Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis with in vitro assessment of the functional capacity of phagocytic cells. Vet Rec. 2011;168:537.
Olivry T, Rivierre C, Jackson HA, Murphy KM, Davidson G, Sousa CA, et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol. 2002;13:77-87.
Saevik BK, Bergvall K, Holm BR, Saijonmaa-Koulumies LE, Hedhammar A, Larsen S, et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol. 2004;15:137-45.
Neto AS, de Farias MR, Pimpao CT, Quitzan JG, Anater A. Efficacy of cyclosporine in the control of atopic dermatitis in dogs. Pesq Vet Brasil. 2017;37:729-33.
Plevnik A, Kobal S, Domanjko-Petric A, Kotnik T. The efficacy of antihistamine fexodenadine versus methylprednisolone in the treatment of atopic dermatitis in dogs. Slov Vet Res. 2009;46:5-12.
Steffan J, Alexander D, Brovedani F, Fisch RD. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol. 2003;14:11-22.
Carlotti DN, Boulet M, Ducret J, Machicote G, Jasmin P, Rème CA, et al. The use of recombinant omega interferon therapy in canine atopic dermatitis: a double-blind controlled study. Vet Dermatol. 2009;20:405-11.
Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26:23-e28.
Nuttall TJ, Mcewan NA, Bensignor E, Cornegliani L, Löwenstein C, Rème CA. Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Vet Dermatol. 2012;23:4-e2.
Olivry T, Steffan J, Fisch RD, Prelaud P, Guaguere E, Fontaine J, et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc. 2002;221:370-7.
Steffan J, Parks C, Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc. 2005;226:1855-63.
Müller MR, Linek M, Löwenstein C, Röthig A, Doucette K, Thorstensen K, et al. Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis. Vet J. 2016;210:77-81.
Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24:587-e142.
Hsiao YH, Chen C, Willemse T. Effects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial. J Vet Sci. 2016;17:549-53.
Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial. Vet Rec. 2013;173:423.
Ewert G, Daens T. Traitement de la dermatite atopique canine par un copolymère d'acide gras : une étude comparative en double aveugle [Treatment of canine atopic dermatitis by a fatty acid copolymer: comparative double blind study]. Prat Méd Chirurg Anim Comp. 2001;36:401-8.
Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, et al. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Vet Dermatol. 2011;22:554-64.
Nuttall T, Mueller R, Bensignor E, Verde M, Noli C, Schmidt V, et al. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol. 2009;20:191-8.
Lourenço AM, Schmidt V, São Braz B, Nóbrega D, Nunes T, Duarte-Correia JH, et al. Efficacy of proactive long-term maintenance therapy of canine atopic dermatitis with 0.0584% hydrocortisone aceponate spray: a double-blind placebo controlled pilot study. Vet Dermatol. 2016;27:88-e25.
Ahlstrom LA, Mason KV, Mills PC. Barazone decreases skin lesions and pruritus and increases quality of life in dogs with atopic dermatitis: a randomized, blinded, placebo-controlled trial. J Vet Pharmacol Ther. 2010;33:573-82.
Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol. 2005;16:52-60.
Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol. 2004;15:294-303.
Marsella R, Nicklin CF. Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. Vet Dermatol. 2002;13:203-10.
Puigdemont A, Brazís P, Ordeix L, Dalmau A, Fuertes E, Olivar A, et al. Efficacy of a new topical cyclosporine A formulation in the treatment of atopic dermatitis in dogs. Vet J. 2013;197:280-5.
Iwasaki T, Hasegawa A. A randomized comparative clinical trial of recombinant canine interferon-γ (KT-100) in atopic dogs using antihistamine as control. Vet Dermatol. 2006;17:195-200.
Yasukawa K, Saito S, Kubo T, Shibasaki Y, Yamaoka K, Hachimura H, et al. Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Vet Dermatol. 2010;21:42-9.
Baddaky-Taugb⊘l B, Vroom MW, Nordberg L, Leistra MHG, Sinke JD, Hovenier R, et al. A randomized, controlled, double-blinded, multicentre study on the efficacy of a diet rich in fish oil and borage oil in the control of canine atopic dermatitis In: Hillier A, Foster AP, Kwochka KW, editors. Advances in veterinary dermatology, Vol. 5. Oxford, UK: Blackwell; 2005. p. 173-87.
Bensignor E, Morgan DM, Nuttall T. Efficacy of an essential fatty acid-enriched diet in managing canine atopic dermatitis: a randomized, single-blinded, cross-over study. Vet Dermatol. 2008;19:156-62.
Bond R, Lloyd DH. A double-blind comparison of olive oil and a combination of evening primrose oil and fish oil in the management of canine atopy. Vet Rec. 1992;131:558-60.
Bond R, Lloyd DH. Randomized single-blind comparison of an evening primrose oil and fish oil combination and concentrates of these oils in the management of canine atopy. Vet Dermatol. 1992;3:215-9.
Bond R, Lloyd DH. Double-blind comparison of three concentrated essential fatty acid supplements in the management of canine atopy. Vet Dermatol. 1993;4:185-9.
Harvey RG. A blinded, placebo-controlled study of the efficacy of borage seed oil and fish oil in the management of canine atopy. Vet Rec. 1999;144:405-7.
Noli C, Scarampella F. Efficacia dell'olio di semi di ribes nero nella dermatite atopica del cane: uno studio in doppio cieco controllato da placebo [Efficacy of blackcurrant seed oil in canine atopic dermatitis: a double blind placebo controlled study]. Veterinaria Cremona. 2002;16:55-60.
Noli C, Carta G, Cordeddu L, Melis MP, Murru E, Banni S. Conjugated linoleic acid and black currant seed oil in the treatment of canine atopic dermatitis: a preliminary report. Vet J. 2007;173:413-21.
Noli C, Galzerano M, Toma S. Efficacia della somministrazione di olio di semi di ribes nero nella prevenzione del prurito e dei segni clinici della dermatite atopica stagionale. Summa, Animali da Compagnia. 2009;26:21-7.
Scarff DH, Lloyd DH. Double blind, placebo-controlled, crossover study of evening primrose oil in the treatment of canine atopy. Vet Rec. 1992;131:97-9.
Singh SK, Dimri U, Saxena SK, Jadhav RK. Therapeutic management of canine atopic dermatitis by combination of pentoxifylline and PUFAs. J Vet Pharmacol Ther. 2010;33:495-8.
Sture GH, Lloyd DH. Canine atopic disease: therapeutic use of an evening primrose oil and fish oil combination. Vet Rec. 1995;137:169-70.
Bensignor EJ, Fabriès LJ. Use of antipruritic and rehydrating foams on localized lesions of atopic dermatitis in dogs: a small-scale pilot and comparative double-blinded study. Vet Dermatol. 2018;29:446-e150.
Blaskovic M, Rosenkrantz W, Neuber A, Sauter-Louis C, Mueller RS. The effect of a spot-on formulation containing polyunsaturated fatty acids and essential oils on dogs with atopic dermatitis. Vet J. 2014;199:39-43.
Marsella R, Genovese D, Gilmer L, Ahrens K, Gatto H, Navarro C. Investigations on the effects of a topical ceramides-containing emulsion (allerderm spot on) on clinical signs and skin barrier function in dogs with atopic dermatitis: a double-blinded, randomized, controlled study. Int J Appl Res Vet Med. 2013;11:110-6.
Marsella R, Cornegliani L, Ozmen I, Bohannon M, Ahrens K, Santoro D. Randomized, double-blinded, placebo-controlled pilot study on the effects of topical blackcurrant emulsion enriched in essential fatty acids, ceramides and 18-beta glycyrrhetinic acid on clinical signs and skin barrier function in dogs with atopic dermatitis. Vet Dermatol. 2017;28:577-e140.
Colombo S, Hill PB, Shaw DJ, Thoday KL. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study. Vet Dermatol. 2005;16:162-70.
Mueller RS, Fieseler KV, Zabel S, Rosychuk RAW. Conventional and rush allergen-specific immunotherapy in the treatment of canine atopic dermatitis In: Hillier A, Foster AP, Kwochka KW, editors. Advances in veterinary dermatology, Vol. 5. Oxford, UK: Blackwell Publishing; 2005. p. 60-9.
Willemse A, Van den Brom WE, Rijnberk A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assoc. 1984;184:1277-80.
Willemse T, Bardagi M, Carlotti DN, Ferrer L, Fondati A, Fontaine J, et al. Dermatophagoides farinae-specific immunotherapy in atopic dogs with hypersensitivity to multiple allergens: a randomised, double blind, placebo-controlled study. Vet J. 2009;180:337-42.
Park JH, Park SJ, Lee WH. Efficacy of half dose house dust mites-specific immunotherapy on canine atopic dermatitis. J Vet Clin. 2017;34:18-22.
Olivry T, Banovic F. Treatment of canine atopic dermatitis: time to revise our strategy? Vet Dermatol. 2019;30:87-90.
Olivry T, Bensignor E, Favrot C, Griffin CE, Hill PB, Mueller RS, et al. Development of a core outcome set for therapeutic clinical trials enrolling dogs with atopic dermatitis (COSCAD'18). BMC Vet Res. 2018;14:238.
Zebala JA, Mundell A, Messinger L, Griffin CE, Schuler AD, Kahn SJ. LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy. PLoS One. 2014;9:e108303.
Botoni LS, Torres SMF, Koch SN, Heinemann MB, Costa-Val AP. Comparison of demographic data, disease severity and response to treatment, between dogs with atopic dermatitis and atopic-like dermatitis: a retrospective study. Vet Dermatol. 2019;30:10-e14.
Plant JD, Gortel K, Kovalik M, Polissar NL, Neradilek MB. Development and validation of the Canine Atopic Dermatitis Lesion Index, a scale for the rapid scoring of lesion severity in canine atopic dermatitis. Vet Dermatol. 2012;23:515-e103.
Hill P, Rybníček J, Lau-Gillard P. Correlation between pruritus score and grossly visible erythema in dogs. Vet Dermatol. 2010;21:450-5.
Fleck T, Humphrey W, Coscarelli E. Comparison of the janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Vet Dermatol. 2012;23(Suppl 1):38.
Olivry T, Saridomichelakis M. Evidence-based guidelines for anti-allergic drug withdrawal times before allergen-specific intradermal and IgE serological tests in dogs. Vet Dermatol. 2013;24:225-e49.
Plevnik Kapun A, Salobir J, Levart A, Tavčar Kalcher G, Nemec Svete A, Kotnik T. Vitamin E supplementation in canine atopic dermatitis: improvement of clinical signs and effects on oxidative stress markers. Vet Rec. 2014;175:560.
Steffan J, Horn J, Gruet P, Strehlau G, Fondati A, Ferrer L, et al. Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methylprednisolone. Vet Rec. 2004;154:681-4.
Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling H-J, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317-24.